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The function of natural killer (NK) cells is controlled by several activating and inhibitory
receptors, including the family of killer-immunoglobulin-like receptors (KIRs). One distinc-
tive feature of KIRs is the extensive number of various haplotypes generated by the gene
content within the KIR gene locus as well as by highly polymorphic members of the KIR
gene family, namely KIR3DL1/S1.Within the KIR3DL1/S1 gene locus, KIR3DS1 represents
a conserved allelic variant and displays other unique features in comparison to the highly
polymorphic KIR3DL1 allele. KIR3DS1 is present in all human populations and belongs
to the KIR haplotype group B. KIR3DS1 encodes for an activating receptor featuring the
characteristic short cytoplasmic tail and a positively charged residue within the transmem-
brane domain, which allows recruitment of the ITAM-bearing adaptor molecule DAP12.
Although HLA class I molecules are thought to represent natural KIR ligands, and HLA-Bw4
molecules serve as ligands for KIR3DL1, the ligand for KIR3DS1 still needs to be identi-
ﬁed. Despite the lack of formal evidence for an interaction of KIR3DS1 with HLA-Bw4-I80
or any other HLA class I subtype to date, a growing number of associations between the
presence of KIR3DS1 and the outcome of viral infections have been described. Especially,
the potential protective role of KIR3DS1 in combination with HLA-Bw4-I80 in the context
of HIV-1 infection has been studied intensively. In addition, a number of recent studies
have associated the presence or absence of KIR3DS1 with the occurrence and outcome of
some malignancies, autoimmune diseases, and graft-versus-host disease (GVHD). In this
review, we summarize the present knowledge regarding the characteristics of KIRD3S1
and discuss its role in various human diseases.
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INTRODUCTION
Killer-immunoglobulin (Ig)-like receptors (KIRs) represent a fam-
ily of activating and inhibitory receptors expressedonnatural killer
(NK) cells that shape and regulateNKcell functions (Moretta et al.,
1993). All human KIRs share common structural features includ-
ing a cytoplasmic domain, a transmembrane domain and either
two or three Ig-like extracellular domains (D0, D1, and D2). Each
of these structural domains has a functional role with regards
to ligand speciﬁcity and signal transduction after engagement
of the respective receptor. Based on the number of extracellu-
lar domains, KIR proteins are classiﬁed as KIR2D (two domains)
and KIR3D (three domains) receptors. KIR2D receptors can be
further subdivided into a type I and type II group depending
on the characteristics of the two extracellular domains. Type I
KIR2D proteins, such as KIR2DL1-3 and KIR2DS1-5, exhibit a
D2 and D1 domain. In contrast, KIR2DL4 and KIR2DL5 encode
for type II KIR2D proteins lacking the D1 domain but comprising
a D0 domain similar to the membrane-distal domain of KIR3D
proteins.
The intracellular domains of KIRs feature either a short or a
long cytoplasmic tail (S or L in the nomenclature, respectively).
The long cytoplasmic tail contains two immune tyrosine-based
inhibitory motifs (ITIM) which lead to the transduction of an
inhibitory signal and thus deﬁnes inhibitoryKIRs. In contrast, KIR
genes encoding for activating receptors possess short cytoplasmic
tails, which have a positively charged amino acid residue in their
transmembrane region. This allows recruitment of the DAP12
adaptor molecule that contains an immunoreceptor tyrosine-
based activating motif (ITAM) and transmits an activating signal.
An exception is KIR2DL4, which contains only one ITIM within
the long cytoplasmic tail and additionally possesses a charged
residue, thus, making it capable of triggering both inhibitory and
activating signals (Faure and Long, 2002).
Within the 14 described human KIRs, KIR3DS1 displays sev-
eral unique features compared, in particular, to its inhibitory
counterpart KIR3DL1. KIR3DS1 represents the only activating
receptor with three extracellular domains. Moreover, in con-
trast to the highly polymorphic KIR3DL1, KIR3DS1 is almost
monomorphic (Norman et al., 2007; Parham et al., 2011). The
interactions between KIR3DL1 and its natural ligands, HLA class
I molecules of the HLA-Bw4 family have been studied inten-
sively and conﬁrmed by crystal structures (Vivian et al., 2011).
In contrast, the natural ligand of KIR3DS1 has yet to be iden-
tiﬁed. Recent genetic and functional studies have suggested that
certain HLA-Bw4 molecules containing an isoleucine in position
80 (HLA-Bw4-I80) are a potential putative ligand for KIR3DS1
(Martin et al., 2002; Alter et al., 2007, 2009). However, despite
several attempts by different groups, direct interactions between
KIR3DS1 and HLA-Bw4 molecules have not yet been demon-
strated (Carr et al., 2007; Gillespie et al., 2007; O’Connor et al.,
2007), with the exception of one report by Li et al. (2010) suggest-
ing interactions betweenKIR3DS1 and theHLA-Bw4-T80 allotype
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HLA-B*2705. However, the study itself displayed some limitations,
which include the lack of adequate negative controls to prove that
binding of KIR3DS1 to the HLA/peptide complex was speciﬁc.
Nevertheless, several studies have observed signiﬁcant associations
between the presence of KIR3DS1 and the outcome of human dis-
ease, suggesting an undiscovered role of KIR3DS1 in modulating
NK cell function (Martin et al., 2002; Lopez-Vazquez et al., 2005;
Gabriel et al., 2010).
EVOLUTION AND GENETICS
In humans, KIR3DL1/S1 is clustered with other genes of the KIR
family within a 100–200 kb region of the leukocyte receptor com-
plex (LRC) on chromosome 19 (19q13.4; Trowsdale, 2001). The
KIR locus can be divided into a centromeric and a telomeric
part, which are ﬂanked by so called framework genes (Wilson
et al., 2000). The centromeric region is conﬁned by KIR3DL3 and
KIR3DP1, while the telomeric region of the KIR gene locus is
enclosed by KIR2DL4 and KIR3DL2. Within the region between
these framework genes, the numbers and types of KIRs present
within a given individual are highly variable resulting in extensive
numbers of different haplotypes. The current KIR genes and the
resulting haplotypes display a snapshot of the rapid evolution of
the KIR gene locus that is driven by selection. The close proxim-
ity of the KIR genes within the centromeric and telomeric region
and the organization of the KIR locus in a head-to-tail fashion
probably facilitated gene expansion by duplication and recombi-
nation, and is reﬂected by the substantial linkage disequilibrium
between KIRs (Gourraud et al., 2010), e.g., between KIR3DS1 and
KIR2DS1 (Hollenbach et al., 2010). In addition, unequal crossover
and generation of extended KIR haplotypes with multiple copies
of an individual gene have been described for KIR3DL1/S1 and
KIR2DL4 (Martin et al., 2003; Williams et al., 2003).
KIR haplotypes can be generally distinguished into two groups,
A andB,whichnot only reﬂect differences in their gene content and
allelic variability but also their contribution to the susceptibility of
various diseases (Uhrberg et al., 1997; Hsu et al., 2002;Marsh et al.,
2003). Individuals encoding the KIR3DS1 gene are considered to
have the KIR haplotype B, which is deﬁned by the presence of at
least one of the following genes: KIR2DL5, KIR2DS1, KIR2DS2,
KIR2DS3, KIR2DS5, and KIR3DS1. Haplotype A is deﬁned by the
absence of the above genes, respectively. In contrast to theKIRhap-
lotype A, in which genetic variability is created by a broad allelic
variance within each KIR gene, variability within B haplotypes is
achieved by the presence or absence of most of the activating KIR
genes andKIR2DL5. Hence, alleles of activating KIRs account only
for a minority of KIR alleles (Marsh et al., 2003; Robinson et al.,
2010). This suggests a general evolutionary concept inwhich allelic
variance of activating KIRs is either limited by natural selection
potentially due to increased occurrence of autoimmune diseases,
or is not required because of the vast possible combinations result-
ing from gene arrangements. An alternative hypothesis is that the
limited diversiﬁcationof activatingKIRs simply reﬂects the shorter
time period since the ﬁrst appearance of activating KIRs as com-
pared to the ancestral inhibitory KIR proteins. Nevertheless, KIR
haplotype groupA aswell as groupB are present in all human pop-
ulation indicating an evolutionary advantage for the maintenance
of both haplotype groups (Gendzekhadze et al., 2006, 2009).
The KIR3DL1/S1 gene locus displays a unique feature of con-
taining reciprocal subsets of allotypes encoding either for the
inhibitory receptor KIR3DL1 or the activating receptor KIR3DS1
(Campbell and Purdy, 2011). While KIR3DL1 allotypes exhibit a
high rate of single nucleotide polymorphisms (SNPs), KIR3DS1 is
almost monomorphic (Norman et al., 2007; Parham et al., 2011).
As a consequence, most of the approximately 70 known allotypes
of KIR3DL1/S1 account for KIR3DL1. Because of its opposing
functional characteristic in comparison to KIR3DL1, KIR3DS1
was initially considered to be the product of a discrete gene
(Valiante et al., 1997). However, further segregation studies identi-
ﬁed KIR3DS1 as a functional allele of the KIR3DL1/S1 gene locus
(Marsh et al., 2003; Traherne et al., 2010).
The evolutionary history of KIR3DL1/S1 can be traced back
before the radiation of the placental mammals, approximately 135
million ago. The ancestral founder gene KIR3D diverged upon
gene duplication into KIR3DX and KIR3DL (Sambrook et al.,
2006; Guethlein et al., 2007). While KIR3DX remained a pseu-
dogene within the leukocyte Ig-like receptors (LILR) gene locus,
KIR3DL expanded and evolved rapidly through duplication and
recombination forming diverse lineages within simian primates.
Based on ancestral inhibitory KIRs with their characteristic ITIMs
located within the long cytoplasmic tail, the appearance of KIRs
with activating properties resulted from new mutations within
the TM and the cytoplasmic tail (Abi-Rached and Parham, 2005).
Elimination of ITIMs that account for the suppressive proper-
ties of inhibitory KIRs resulted from mutations or stop codons
leading to alterations of length of the cytoplasmic tail. This pro-
cess was accompanied by the introduction of a positively charged
amino acid residue within the TM allowing activating KIRs to
interact with the DAP12 adaptor molecule, which possesses an
ITAM (Lanier et al., 1998; Vivier et al., 2004).
Based on sequences as well as on the presence and frequency
of KIR3DL1/S1 allotypes in the human populations, KIR3DL1/S1
alleles can be classiﬁed into three distinct phylogenetic lineages
that evolved more than 3 million years ago: 3DL1*015-like,
3DL1*005-like, and 3DS1*013-like (Norman et al., 2007; Parham
et al., 2011). In line with this, the allotypes KIR3DL1*015,
KIR3DL1*005, and 3DS1*01301 each represent the prototypi-
cal alleles of the lineages due to their abundance in all human
populations. Although KIR3DS1*01301 is the most abundant
KIR3DL1/S1 allele worldwide, lower allele frequencies of KIR3DS1
in sub-Saharan Africans have been described, indicating that nat-
ural selection for inhibitory alleles of KIR3DL1/S1 is potentially
due to increased exposure to a wide variety of pathogens over
a long time period (Norman et al., 2007). In this context, Abi-
Rached and Parham (2005) introduced a provocative hypothesis
that might provide an explanation for the maintenance and diver-
siﬁcation of activating KIRs as a result of balanced selection of
the KIR haplotype groups A and B (enriched for activating KIRs)
observed in modern human populations. The authors postulated
that activating KIRs undergo an initial phase of positive selection,
which is driven by an increased resistance to pathogens and repro-
ductive success. This phase is then followed by a period of negative
selection that is caused by the negative effects of autoimmunity.
Although the presence and maintenance of both KIR haplotype
groups A and B in all human populations are in line with this
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hypothesis and indicate a complementary function of the KIR
haplotype groups A and B, the underlying mechanisms are still
under discussion. In particular, the epidemiological studies onKIR
and reproduction that have suggested an association of maternal
homozygosity for KIR haplotype group A with an increased risk
for pregnancy complications such as preeclampsia and recurrent
miscarriage are so far limited to KIR2D molecules (Hiby et al.,
2004, 2008, 2010).
REGULATION OF TRANSCRIPTION AND EXPRESSION
The expression patterns of human KIR proteins within a single
individual’s NK cell population are highly complex. They may
be affected by many factors including frequency, expression lev-
els, and co-expression of other KIRs. These determinants are
controlled by genetic and epigenetic factors some of which have
been identiﬁed over the past years, in particular for KIR3DL1/S1.
Key players in the regulation of KIR expression are the promoter
regions, which display different afﬁnities to transcription factors
due to sequence variations.
Similar to most of the KIR genes, transcription of KIR3DL1/S1
is regulated by a∼2 kb small region upstreamof the coding region.
With the exception of KIR2DL4, the promoters within this region
are highly homologous throughout the KIR locus (Wilson et al.,
2000). The expression of the encoded KIR genes is regulated by
the degree of DNA methylation, which prevents transcription in
the early stages of NK cell development (Chan et al., 2005; San-
tourlidis et al., 2008). During maturation and education of NK
cells, the KIR expression pattern of each NK cell is thought to be
deﬁned by hypo- or hypermethylation of the distinct promoters
(Santourlidis et al., 2002; Chan et al., 2003). The level of expres-
sion of KIR3DL1/S1 is determined by a complex interplay of the
activity of two promoters within the intergenic region upstream
of KIR3DL1/S1. While the distal promoter only transcribes sense
mRNA, the proximal promoter features a bidirectional promoter
activity, producing either sense or antisense mRNA in a proba-
bilistic fashion resulting in either silenced or increased expression
of KIR3DL1/S1 (Stewart et al., 2003; van Bergen et al., 2005; Davies
et al., 2007; Stulberg et al., 2007). SNPs within the proximal pro-
moters determine the activity and transcription of sense and
antisense mRNA, resulting in different expression levels and fre-
quencies of the different KIR3DL1/S1 alleles (Yawata et al., 2006;
Li et al., 2008).
However, these SNPs can only partially explain the discor-
dant observation of low transcription ratio and frequency of
KIR3DS1 in NK cells. Depending on homo- or heterozygosity of
the KIR3DS1 allele, the frequency of NK cells expressing KIR3DS1
can range between ∼40–80 and 10–60% respectively (O’Connor
et al., 2007; Pascal et al., 2007). This indicates the involvement
of other factors inﬂuencing KIR3DS1 expression on NK cells.
In fact, it has been shown that surface expression of KIR3DS1
can be induced by various stimuli, such as IL-2, IL-15, or the
MHC class I deﬁcient K562 cell line (Morvan et al., 2009). More-
over, Yawata et al. (2006) observed increased numbers of NK cells
expressing KIR3DL1 and KIR2DL1 in individuals carrying the
cognate HLA ligands, indicating a possible effect of HLA ligands
on the expression of their respective KIR receptors. Finally, fre-
quency and surface density of KIR3DS1 can be further affected
by copy number variants of KIR3DL1/S1 within the KIR locus
(Pelak et al., 2011). Increased RNA expression and percentage of
KIR3DS1+ NK cells but not KIR3DL1+ NK cells were observed
in individuals with multiple copies of KIR3DL1 alleles, suggesting
an interaction between the expression levels of these two allotypes
that will require further investigations.
Surface expression of KIR3DS1 can be detected by the
KIR3DL1/S1-speciﬁc mAb Z27 (Carr et al., 2007; O’Connor et al.,
2007; Trundley et al., 2007). In combination with the KIR3DL1-
speciﬁc mAb DX9 (Litwin et al., 1994), mAb Z27 is used to dis-
criminate cells with regards to their surface expression of KIR3DL1
or KIR3DS1.While Z27 and DX9 antibodies both stain KIR3DL1,
KIR3DS1 is not recognized by DX9, indicating that the antibod-
ies target different epitopes. In line with this, it has been shown
that Tyr200 is a determinant for DX9 recognition of KIR3DL1 but
not for Z27 (Khakoo et al., 2002). Furthermore, different amino
acid residues in position 199 of KIR3DL1 (proline) and KIR3DS1
(leucine) might contribute to the observed different staining pro-
ﬁles. KIR3DS1 displays low ﬂuorescence intensity when stained
with Z27. Whether this reﬂects a low binding afﬁnity of Z27
to KIR3DS1 or an overall low surface expression of KIR3DS1
in comparison to KIR3DL1 is unclear. In contrast, KIR3DL1
displays various expression levels depending on the respective
allotype, which can be discriminated into alleles with high (e.g.,
KIR3DL1*001) and low surface density (e.g., KIR3DL1*005), as
well as a null variant (KIR3DL1*004) that is not expressed on the
cell surface (Gardiner et al., 2001; Pando et al., 2003; Yawata et al.,
2006). Of note, similar to the KIR3DL1*004 allele that encodes
for a KIR3DL1molecule that is not expressed on the cell surface, a
KIR3DS1null allele (KIR3DS1*049N) has also been identiﬁed (Pas-
cal et al., 2007). A complex deletion/substitutionmutation in exon
4 resulting in a premature stop codon was identiﬁed as the under-
lying mechanism. A subsequent study analyzing allele frequencies
ofKIR3DS1*049N in the different populationsworldwide revealed
that this allele is very rare, suggesting thatKIR3DS1*049N is prob-
ably not importantly involved in disease associations described for
KIR3DS1 (Martin et al., 2007a).
Despite these recent advances in our understanding of the reg-
ulation of KIR expression on a single cell level, the underlying
mechanisms of how the KIR expression patterns are shaped are
still not fully understood. In general, cytokines and the presence
cognateHLA ligandsmay be involved duringmaturation and edu-
cation of NK cells thus inﬂuencing KIR expression patterns within
the NK cell population. With regards to KIR3DS1, further studies
are needed to fully understand how expression of KIR3DS1 is reg-
ulated and to determine the potential functional consequences of
increased expression.
LIGAND SPECIFICITY OF KIR3DL1 AND KIR3DS1
Classical and non-classical HLA class I molecules can serve as
natural ligands for several inhibitory and activating KIRs (Bias-
soni et al., 1995; Rajagopalan and Long, 1999; Hansasuta et al.,
2004). Moreover, crystal structures of certain KIR/peptide/HLA
complexes have clariﬁed the molecular interactions between KIR
and peptide-loaded HLA molecules (Boyington et al., 2000; Fan
et al., 2001; Vivian et al., 2011), including the KIR3DL1 and
HLA-B57 pair.
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KIR3DL1 recognizes HLA-A and -B molecules containing the
HLA-Bw4 motif (Cella et al., 1994; Gumperz et al., 1995; Stern
et al., 2008). However,KIR3DL1displays differential afﬁnities to its
cognate HLA class I ligands depending on the encoding KIR3DL1
allele, the respectiveHLA allele, and theHLA class I-presented epi-
tope (Carr et al., 2005; Thananchai et al., 2007; Foley et al., 2008;
Fadda et al., 2011). Minor changes in the amino acid sequence
of KIR3DL1 in regions interacting with the peptide/HLA com-
plex can lead to either increased afﬁnity or complete abrogation
of binding. Two polymorphisms at position 238 (D2 domain)
and 320 (TM) that discriminate KIR3DL1*002 and KIR3DL1*007
were identiﬁed to affect the ability of HLA-Bw4 ligands to inhibit
KIR3DL1*002- and KIR3DL1*007-expressing NK leukemia cell
lines (Carr et al., 2005). Moreover, it has been shown that the dif-
ferential binding of KIR3DL1 to HLA-A*2402 in complex with
an HIV-1 peptide is mediated by dimorphic motifs in the D0 and
D1/D2 domains of KIR3DL1 (Sharma et al., 2009). Thus, single
amino acid substitutions within KIR3DL1 play a critical role in
the binding afﬁnity to HLA ligands and can provide insights into
themolecularmechanisms that regulate KIR/HLA interactions. In
addition, it has been shown that a single amino acid change in the
KIR2D receptors deﬁnes the ability of KIR2D receptors to recog-
nize either HLA-C group 1 or 2 receptors. This suggests a unifying
concept of ligand speciﬁcity and afﬁnity for KIR proteins (Winter
and Long, 1997; Moesta et al., 2008).
The binding afﬁnity of KIR3DL1 to its cognate HLA class I
molecules is further dependent on the HLA class I presented
peptides. In particular, amino acid residues in position 7 and
8 of the HLA-bound peptide seem to be pivotal in either pro-
moting or abrogating binding of KIRs to their cognate HLA
class I molecules (Peruzzi et al., 1996; Mandelboim et al., 1997;
Rajagopalan and Long, 1997; Vales-Gomez et al., 1998; Hansasuta
et al., 2004; Fadda et al., 2010). In this context, it has been shown
that binding of KIR3DL1 to HLA-B57 was affected by a variety
of HIV-1-derived peptides (Fadda et al., 2011). Crystal structures
of KIR/HLA/peptide complexes conﬁrmed a direct interaction
between residues 7 and 8 of the HLA-presented peptide and KIRs
(Boyington et al., 2000; Vivian et al., 2011). Overall, amino acid
polymorphisms within KIR proteins and HLA class I-presented
epitopes represent two pivotalmechanisms deﬁning the binding of
KIR proteins to their cognate HLA ligands. These polymorphisms
might provide NK cells with an ability to distinguish changes of
the epitope repertoire presented by HLA class I on virus-infected
and transformed cells.
Despite a high sequence homology (>95%) between KIR3DS1
andKIR3DL1 (Dohring et al., 1996), direct binding of KIR3DS1 to
HLA class I molecules has not been convincingly demonstrated to
date. However, several genetic studies have suggested a functional
interaction between KIR3DS1 and HLA-Bw4molecules in human
diseases (Martin et al., 2002; Lopez-Vazquez et al., 2005). Mar-
tin et al. (2002) ﬁrst identiﬁed an association between KIR3DS1
and certain HLA-B alleles and the progression to AIDS. The com-
bined presence of KIR3DS1 and HLA-B alleles that encode an
isoleucine at position 80 (HLA-Bw4-I80) was associated with sig-
niﬁcantly slower progression to AIDS, while the absence of either
KIR3DS1 or HLA-Bw4-I80 alleles led to the loss of the observed
effect. The combined KIR3DS1/HLA-Bw4-I80 genotype was also
associated with decreased susceptibility for the development of
hepatocellular carcinoma in patients with chronic hepatitis C virus
(HCV; Lopez-Vazquez et al., 2005). These data implicate a poten-
tial interaction between HLA-Bw4-I80 molecules and KIR3DS1,
and suggested a functional role for KIR3DS1 in NK cell-mediated
recognition of HIV-1-infected as well as transformed cells. How-
ever, not all studies have demonstrated a synergistic protective
effect of the compounded genotype in the context of HIV-1
infection. Other groups have shown that the beneﬁcial effects of
HLA-Bw4-I80 and KIR3DS1 are independent and not linked to
each other (Barbour et al., 2007), or have observed a detrimental
effect of carriage of KIR3DS1 on progression of HIV-1 infection
(Gaudieri et al., 2005).
Based on these genetic associations studies, several groups have
sought to assess a direct interaction of KIR3DS1 and HLA-Bw4-
I80 class I molecules. Gillespie et al. (2007) used multiple Bw4-I80
MHC class I tetramers refolded with a broad panel of HIV-1
peptide epitopes to detect tetramer binding to KIR3DS1 tran-
siently expressed on 293-T cells, while O’Connor et al. (2007)
used a luciferase reporter assay to detect activation of KIR3DS1-
transfected Jurkat cells in response to stimulation with 721.221
cells transfected with multiple HLA-Bw4 molecules. Although
these methods were successfully used to identify HLA/peptide
complexes as ligands for KIR3DL1, the same assays failed to
show any detectable interaction with KIR3DS1. Another approach
was chosen by Carr et al. (2007) using KIR3DS1–IgG fusion
constructs to identify binding with HLA-B*5701 transfected
721.221 cells. Again, the authors were not able to identify
HLA-Bw4-I80 molecules as a ligand for KIR3DS1. In contrast
to KIR3DL1+ NK cells, proliferation and cytotoxic capacity
of KIR3DS1+ NK cells were not affected by HLA-Bw4+ irra-
diated allogeneic EBV-B cell lines (Morvan et al., 2008, 2009).
The one exception is a recent study by Li et al. (2010) suggest-
ing interactions between KIR3DS1 and HLA-Bw4-T80 allotype
HLA-B*2705 by using surface plasmon resonance (SPR) tech-
nology. However, there were some limitations in the design of
these studies, including the lack of negative controls that demon-
strate that binding of KIR3DS1 to the HLA/peptide complex
is speciﬁc. Overall, additional studies will be needed to deter-
mine whether KIR3DS1 can bind to HLA-Bw4 molecules, and
whether these interactions depend on the HLA class I-presented
epitope.
These studies which have investigated the allele-speciﬁc charac-
teristics of KIR3DL1have providedhelpful insights in the potential
molecular interaction betweenKIR3DS1 andHLA-Bw4molecules
(see Table 1). Despite the high level of homology to KIR3DL1,
KIR3DS1 differs in at least six amino acid positions through-
out the extracellular domains, including positions 163, 166 (D1
domain), and 199 (D2 domain; Gardiner et al., 2001). Introduc-
tion of any of these KIR3DS1-speciﬁc amino acid residues into
a KIR3DL1*001 molecule as performed by Sharma et al. (2009)
led to complete abrogation of binding to HLA-A*2402, a con-
ﬁrmed ligand for KIR3DL1. In this context, Thomas et al. (2008)
identiﬁed a natural KIR3DL1 allotype (KIR3DL1*054) that shares
the same amino acid residues at position 138, 163, and 166 of
the D1 domain with KIR3DS1*013. Introduction of these sin-
gle amino acid substitutions at position 138, 163, and 166 into
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Table 1 | Effects of selected amino acid variations within KIR3DL1/S1 on antibody recognition and HLA binding.
Domain Position 3DS1a 3DL1a Effect on antibody staining and HLA bindingb Reference
D0 58 G S DX9 and Z27 binding: reductionc Sharma et al. (2009)
D0 92 M V DX9 and Z27 binding: reductionc Sharma et al. (2009)
D1 138 W G DX9 and Z27 binding: no effectc, reductionc Sharma et al. (2009), O’Connor et al. (2011)
Tetramer binding (HLA-B*5701): no effectd Vivian et al. (2011)
Tetramer binding (HLA-A*2402): reductionc O’Connor et al. (2011)
Tetramer binding (HLA-B*2705): abrogationc O’Connor et al. (2011)
D1 163 S P DX9 and Z27 binding: reductionc, no effectc Sharma et al. (2009), O’Connor et al. (2011)
Tetramer binding (HLA-A*2402): abrogationc, reductionc Sharma et al. (2009), O’Connor et al. (2011)
Tetramer binding (HLA-B*2705): abrogationc O’Connor et al. (2011)
D1 166 R L DX9 binding: reductionc Sharma et al. (2009)
Tetramer binding (HLA-A*2402): abrogationc Sharma et al. (2009), O’Connor et al. (2011)
Tetramer binding (HLA-B*5701): reductiond Vivian et al. (2011)
Tetramer binding (HLA-B*2705): abrogationc O’Connor et al. (2011)
D2 199 L P DX9 and Z27 binding: no effectc Sharma et al. (2009)
Tetramer binding (HLA-A*2402): abrogationc Sharma et al. (2009)
Tetramer binding (HLA-B*5701): reductiond Vivian et al. (2011)
aAmino acid residue of KIR3DS1*013 and KIR3DL1*015, respectively; bTetramers folded with the following peptides: HLA-B*5701: LSSPVTKSF (self-peptide), HLA-
A*2402: RYPLTFGW (HIV nef), HLA-B*2705: TSTLQEQIGW (HIV gag); cEffect observed when aa introduced in KIR3DL1*015; dEffect observed when aa introduced
in KIR3DL1*001.
KIR3DL1*01502 also lead to loss of recognition of HLA-A*2402 or
HLA-B*2705 (O’Connor et al., 2011) conﬁrming the importance
of these residues. Moreover, the reverse introduction of KIR3DL1-
speciﬁc residues in KIR3DS1*013 led to measurable binding of
HLA-A*2402 but also revealed a complex interaction between dis-
tinct KIR3DS1-speciﬁc residues and HLA class I residues. While
the substitution of tryptophan to glycine at position 138 seemed to
be sufﬁcient to reconstituteHLA binding, the additional introduc-
tion of proline at position 199 resulted in the loss of HLA binding.
Interestingly, the existence of one KIR3DS1 allotype (3DS1*014)
carrying glycine at position 138 has been described previously
(Crum et al., 2000; Norman et al., 2007). This potentially rep-
resents an intermediate step in the evolution of the activating
KIR3DS1 from the ancestral inhibitory KIR. The extremely low
frequency of this particular HLA-Bw4 binding KIR3DS1 allotype
might reﬂect the strong negative effect on selection in the pres-
ence of a KIR3DS1 allele with broad binding afﬁnity to HLA-Bw4
molecules.
The crucial role of these amino acid residues within KIR3DL1
and KIR3DS1 in HLA binding was also conﬁrmed by the recent
description of the crystal structure of KIR3DL1*001 in com-
plex with self-peptide-loaded HLA-B*5701 (Vivian et al., 2011).
The authors identiﬁed a “hotspot” within the D1/D2 domain
of KIR3DL1 that contains three loops (165–167, 199–201, and
278–282), which seem to be pivotal for binding to HLA-B57. This
region is altered in KIR3DS1 and might provide an explanation
for why there is no direct interaction between HLA-B*5701 and
KIR3DS1.Whether theKIR3DS1-speciﬁc amino acid residues pre-
clude recognition of other HLA-Bw4-I80 molecules is unknown
and needs to be clariﬁed by additional studies.
It has been shown that binding of KIR to its cognate lig-
and is dependent on the presented peptide (Malnati et al., 1995;
Zappacosta et al., 1997; Maenaka et al., 1999; Stewart et al., 2005;
Thananchai et al., 2007) thus raising the possibility that KIR3DS1
might bindHLA-Bw4-I80molecules under certain circumstances.
KIR3DL2 recognizes HLA-A*3 and HLA-A*11 molecules only in
the presence of a small number of speciﬁc EBV-derived peptides
(Hansasuta et al., 2004). Hence, KIR3DS1 might recognize HLA-
Bw4 molecules in combination with speciﬁc peptides in a very
restricted fashion. This would prohibit recognition and killing
of self-peptide presenting normal cells and prevent autoimmune
reactions of KIR3DS1+ NK cells. In contrast, it has been shown
that stressed or virus-infected cells undergo alteration in their
presented peptide repertoire (Hickman et al., 2003; Meiring et al.,
2006). It is conceivable that these cells could be detected and killed
by NK cells via engagement of activating KIRs such as KIR3DS1.
However, the controversial discussion as to whether KIR3DS1
recognizes HLA-Bw4 molecules will continue until a direct inter-
action is proven. Thus, alternative hypotheses for effects exerted
by KIR3DS1 on the outcome of certain diseases continue to be a
topic of interest to the ﬁeld.
ROLE OF THE KIR3DS1 IN DISEASES
Several studies have identiﬁed KIR3DS1 to be associated with the
outcome of various diseases (reviewed in Jamil andKhakoo, 2011),
including viral infections, most prominently HIV-1 infection, cer-
tain malignancies, and auto immune diseases (see Table 2). In
particular, the role of KIR3DL1/S1 in viral infections has been
well-accepted since the ﬁrst descriptions of signiﬁcant associations
between the KIR3DL1/S1 gene locus and the outcome of HIV-1
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Table 2 | Selected disease associations of KIR3DS1.
Disease Association when KIR3DS1 is present
Viral infections
HIV-1 Delayed progression to AIDS in combination
with HLA-Bw4-I80 (Martin et al., 2002)
Hepatitis B virus infection Increased rate of spontaneous recovery
(Zhi-Ming et al., 2007)
H1N1 inﬂuenza A Severe pandemic inﬂuenza A infections
(Aranda-Romo et al., 2012)
Malignancies
Hepatocellular carcinoma Reduced risk in combination withHLA-Bw4-
I80 (Lopez-Vazquez et al., 2005)
Hodgkin’s lymphoma Reduced risk (Besson et al., 2007)
Respiratory papillomatosis Reduced risk (Bonagura et al., 2010)
Cervical neoplasia Increased risk (Carrington et al., 2005)
Other
Allogeneic HSCT Decreased progression-free survival
of patients with multiple myeloma
(Gabriel et al., 2010); decreased overall
survival in HLA-Bw4− patients (Gagne et al.,
2009); decreased acute GVHD (Venstrom
et al., 2010)
Ankylosing spondylitis (AS) Increased susceptibility for development of
AS (Lopez-Larrea et al., 2006; Diaz-Pena
et al., 2010)
infection (Martin et al., 2002,2007b). Subsequent studies observed
a protective effect of the combined presence of KIR3DS1 andHLA-
Bw4-I80 alleles in patients with chronic HIV-1 infection. These
ﬁndings include key determinants of progressive HIV-1 infection
such as lower viral load, slower decline of CD4+ T cell count
and delayed progression to AIDS (Martin et al., 2002; Qi et al.,
2006). In addition, in these studies it has been shown that an
increased KIR3DS1 count generated by copy number variants of
KIR3DL1/S1 was associated with a lower viral set point in the
presence of HLA-Bw4-I80 alleles (Pelak et al., 2011).
However, other observations questioned the concept of a syn-
ergistic effect of the KIR3DS1/HLA-Bw4-I80 compound genotype
onHIV-1 disease, or the protective effect of KIR3DS1on the course
of HIV-1 infection. A cohort study conducted by Barbour et al.
(2007) indicated thatKIR3DS1 andHLA-Bw4-I80 might indepen-
dently exert a protective effect on the course of HIV-1 infection.
The authors showed that HIV-1-positive individuals carrying
KIR3DS1 displayed increased CD4+ T cell counts as compared
to those without KIR3DS1 and that carriage of HLA-Bw4-I80 was
associated with lower viral loads. Gaudieri et al. (2005) reported a
detrimental effect of theKIR3DS1 allele which was associated with
an increased hazard ratio for AIDS disease progression.
Another complicating issue is the inconsistency of ﬁndings in
HIV-1 exposed seronegative subjects (HESN) regarding the inﬂu-
ence of KIR3DS1 on HIV-1 acquisition. Two studies described
a protective role of KIR3DS1 in these particular cohorts (Boulet
et al., 2008; Tomescu et al., 2011). In contrast, two studies con-
ducted by Tomescu et al. (2010) and O’Connell et al. (2009) did
not observe an enrichment of KIR3DS1 and HLA-Bw4-I80 alleles
in HESN (Tomescu et al., 2010). This suggests that host factors
other than KIR3DS1 may be involved in the control of HIV-1
infection.
Nevertheless, functional studies in KIR3DS1+ NK cells, in
particular in acute HIV-1 infection, have provided some indica-
tions for an interaction of KIR3DS1 and HLA-Bw4-I80. Results
obtained by Alter et al. (2009) demonstrated an expansion of
KIR3DS1+ NK cells in acute HIV-1 infection, however only in
individuals that also encoded forHLA-Bw4-I80 alleles. In addition,
HLA-Bw4-I80-dependent killing of HIV-1 infected target cells and
inhibition of viral replication by KIR3DS1+ NK cells has been
described (Alter et al., 2007). Although a subsequent study con-
ducted byLong et al. (2008) observed increased IFN-y andCD107a
expression of NK cells in KIR3DS1+ individuals with early HIV-
1 infection, this ﬁnding was independent of the joint carriage of
HLA-Bw4-I80.However, the authors did observe higher IFN-y and
CD107a expression in individuals encoding for bothKIR3DS1 and
HLA-Bw4 alleles, in particular in the presence of the B*58 alleles,
and the lack of detecting a statistical signiﬁcance for higher NK
cell activity in KIR3DS1/HLA-Bw4-I80+ individuals might have
been a consequence of the small sample size. In addition, increased
frequency and antiviral capacity against HIV-1 of KIR3DS1+ NK
cells were recently described in individuals encoding for multiple
copies of KIR3DL1 (Pelak et al., 2011). The results from the study
by Pelak et al. (2011) indicate that KIR3DL1-dependent licensing
of NKcellsmight be involved in shaping a strong antiviral response
of KIR3DS1+NK cells. Higher responsiveness of licensedNK cells
might therefore serve as one potential underlying mechanism for
the protective effect of the combined presence of KIR3DL1 and its
cognateHLA ligands in chronicHIV-1 infection (Kim et al., 2008).
Overall, although a beneﬁcial effect of KIR3DS1 in the context
of HIV-1 infection has been observed in some in vivo and in vitro,
it remains unknown whether this effect is mediated by KIR3DS1
itself or other genes in linkage disequilibrium with KIR3DS1.
Furthermore, it is not clear whether changes in KIR3DL1 copy
numbers in KIR3DS1+ individuals are responsible for this pro-
tective effect or whether this is dependent on the simultaneous
presence of HLA-Bw4-I80.
The role of KIR3DS1 has also been investigated in other viral
infections such as human T-cell leukemia virus type 1 (HTLV-1),
H1N1 inﬂuenza A, and hepatitis B virus infection (HBV). While
no evidence for the participation ofKIR3DS1 in control of HTLV-1
infection was found (O’Connor et al., 2012), carriage of KIR3DS1
and other haplotype B containing KIRs was associated with severe
pandemic inﬂuenza A (H1N1) 2009 infections (Aranda-Romo
et al., 2012). Frequencies of KIR3DS1 as well as KIR2DS1 and
KIR2DL5 were furthermore increased in a group of patients who
spontaneously recovered fromHBV compared to individuals with
chronic HBV infection or healthy controls (Zhi-Ming et al., 2007).
Because of the close proximity of the genes within the KIR locus
and the resulting strong linkage disequilibrium with neighbor-
ing genes, it remains unclear whether the observed effects are
due to a speciﬁc KIR. Furthermore, the mechanisms underlying a
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potential protective effect of speciﬁc KIR genotypes remain to be
elucidated.
Aside from their important role in controlling viral infections,
NK cells can also mediate antitumor immunity (reviewed in Wu
and Lanier, 2003). Association studies investigating the impact
of KIR/HLA haplotypes in selected malignancies have identiﬁed
protective as well as unfavorable KIR/HLA haplotypes, includ-
ing some comprising KIR3DS1 (Arnheim et al., 2005; Purdy and
Campbell, 2009; Karabon et al., 2011). A protective effect of
KIR3DS1 in combination with HLA class I molecules expressing
the HLA-Bw4-I80 epitope in hepatocellular carcinoma has been
observed in patients with chronic HCV infection (Lopez-Vazquez
et al., 2005). The underlying mechanism of this protective geno-
type is not known. It is possible that transformed cells in the
HCV-infected liver encode for a KIR3DS1 ligand and are directly
recognized and killed by KIR3DS1+ NK cells. A decreased risk
for the development of Hodgkin’s lymphoma (HL), a common
lymphoma in young adults, was also identiﬁed in individuals car-
rying KIR3DS1 in familial study with 90 cases and 255 ﬁrst-degree
relatives (Besson et al., 2007). In addition, absence of KIR3DS1
and KIR2DS1, which display strong linkage disequilibrium, was
associated with more frequent occurrence of respiratory papil-
lomatosis (RRP), a rare disease of the larynx and upper airway
caused by human papillomaviruses (HPV)-6/11 (Bonagura et al.,
2010). Of note, all three malignancies described above are caused
or at least promoted by viral infections, indicating a potential
role of KIR3DS1 in the control of the underlying viral infections.
Thus, it is possible that the protective role of KIR3DS1 is due
to the recognition of virus-infected cells by KIR3DS1+ NK cells
similar to other viral infections. In contrast, some studies have
described a detrimental effect of KIR3DS1 in cervical cancer and
on the outcome of unrelated hematopoietic stem cell transplan-
tation (HSCT). An increased susceptibility to the development of
cervical neoplasia in patients carrying KIR3DS1 was identiﬁed by
Carrington et al. (2005). Of note, similar to the above mentioned
RRP, cervical neoplasia is also a HPV-associated disease. However,
in this case the presence of KIR3DS1+ NK cells might be detri-
mental due to incomplete viral control and chronic inﬂammation
that might facilitate the development of cancer.
In a multivariate analysis Gabriel et al. (2010) showed that
progression-free survival of patients with multiple myeloma after
autologous stem cell transplantation was signiﬁcantly decreased
in patients carrying the KIR3DS1 gene. Furthermore, Gagne et al.
(2009) observed the lowest overall survival in HLA-Bw4− patients
withmyelogenousdiseases receivingKIR3DL1+/KIR3DS1+ donor
NK cells during HSCT. In contrast, a beneﬁcial effect of KIR3DS1
in the context of T cell-depleted HSCT has also been observed,
showing a protective effect of donor KIR haplotype B against
leukemic relapse and improved disease-free survival in patients
undergoingHSCT (Verheyden et al., 2005;Marcenaro et al., 2011).
Venstrom et al. (2010) furthermore showed that transplantation
of hematopoietic stem cells from KIR3DS1+ donors was asso-
ciated with decreased acute graft-versus-host disease (GVHD).
Although the underlying mechanism of the observed effects are
not understood, the above studies indicate a potential role of
NK cell licensing in the setting of HSCT as the HLA and KIR
haplotypes of the donor deﬁne NK cell responses in the new host.
Finally, with regards to autoimmune diseases, a growing num-
ber of studies suggest a role for NK cells in disease pathogenesis.
In particular, KIR3DS1 has been associated with the development
and progression of ankylosing spondylitis (AS; reviewed in Diaz-
Pena et al., 2009 and Azuz-Lieberman et al., 2005). AS represents
a prototypic subtype of a group of various related diseases sum-
marized as spondyloarthritis (reviewed in Dougados and Baeten,
2011). The characteristic symptoms include chronic inﬂamma-
tion of the joints and ligaments of the spinal bones that can be
triggered by mechanical or bacterial stress. Although the exact
underlying pathology remains unknown, genetic predisposition
accounts for 80–90% of the cases, and include the presence of
HLA-B27 allotypes as a major risk factor (Thomas and Brown,
2010). Several studies observed enrichment for KIR3DS1 in HLA-
B27+ patients with AS (Lopez-Larrea et al., 2006; Diaz-Pena
et al., 2010), while KIR3DL1 was found to be underrepresented
in patients with AS as compared to HLA-B27+ healthy controls
(Mousavi et al., 2010;Wang et al., 2012).With regards to the ligand
speciﬁcity of KIR3DS1, functional studies investigating a potential
interaction of KIR3DS1 and HLA-B27 in the context of AS have
not been conducted. Moreover, whether the underlying mecha-
nism of the increased susceptibility to the development of AS in
KIR3DS1+ individuals involves a differential activation threshold
of KIR3DS1+ NK or CD8+ T cells is not known. These data
also indicate that the presence of KIR3DS1 is a more important
factor in the development of AS than the absence of protective
KIR3DL1 allotypes. However, it should be noted that other stud-
ies neither observed any signiﬁcant involvement of KIR3DL1/S1 in
the outcome of AS (Harvey et al., 2009), nor identiﬁed other com-
pound KIR genes and HLA allotypes linked to the development
and progression of AS (Diaz-Pena et al., 2008; Jiao et al., 2010;
Tajik et al., 2011).
Taken together, these studies suggest that KIR3DS1 might not
only play a role in the outcome of viral infections, but also in
malignancies, the outcome after HSCT, and auto immune disease.
Additional functional studies of NK cells are required in these
disease settings todeterminewhetherKIR3DS1 exerts its protective
or detrimental effects through modulation of NK cell function, or
by alternative mechanisms.
CONCLUDING REMARKS
An accumulating number of studies have demonstrated the
inﬂuence of KIR3DS1 on the outcome of various human dis-
eases. Furthermore, the ubiquitous presence of KIR3DS1 within
human populations suggests an evolutionary pressure to main-
tain this activating KIR. The lack of a deﬁned ligand for
KIR3DS1 has signiﬁcantly hampered functional studies to deter-
mine the mechanisms underlying KIR3DS1-associated protection
from disease, but might also suggest a restricted engagement of
KIR3DS1 to prevent killing of normal cells and thus damage of
the host.
ACKNOWLEDGMENTS
This study was supported by the NIH (R01 AI066031), the Doris
Duke Charitable Foundation, and the Ragon Institute of MGH,
MITandHarvard.We thankCormacCosgrove andSagarA.Vaidya
for critical review of this manuscript.
www.frontiersin.org November 2012 | Volume 3 | Article 326 | 7
“ﬁmmu-03-00326” — 2012/11/1 — 14:43 — page 8 — #8
Körner and Altfeld Biology of KIR3DS1
REFERENCES
Abi-Rached, L., and Parham, P. (2005).
Natural selection drives recurrent
formation of activating killer cell
immunoglobulin-like receptor and
Ly49 from inhibitory homologues. J.
Exp. Med. 201, 1319–1332.
Alter, G.,Martin,M. P., Teigen, N., Carr,
W. H., Suscovich, T. J., Schneidewind,
A., et al. (2007). Differential natu-
ral killer cell-mediated inhibition of
HIV-1 replication based on distinct
KIR/HLA subtypes. J. Exp. Med. 204,
3027–3036.
Alter, G., Rihn, S., Walter, K., Nolt-
ing, A., Martin, M., Rosenberg, E.
S., et al. (2009). HLA class I subtype-
dependent expansion of KIR3DS1+
and KIR3DL1+ NK cells dur-
ing acute human immunodeﬁciency
virus type 1 infection. J. Virol. 83,
6798–6805.
Aranda-Romo, S., Garcia-Sepulveda, C.
A., Comas-Garcia, A., Lovato-Salas,
F., Salgado-Bustamante, M., Gomez-
Gomez, A., et al. (2012). Killer-
cell immunoglobulin-like receptors
(KIR) in severe A (H1N1) 2009
inﬂuenza infections. Immunogenetics
64, 653–662.
Arnheim, L., Dillner, J., and Sanjeevi,
C. B. (2005). A population-based
cohort study of KIR genes and geno-
types in relation to cervical intraep-
ithelial neoplasia. Tissue Antigens 65,
252–259.
Azuz-Lieberman, N., Markel, G.,
Mizrahi, S., Gazit, R., Hanna, J.,
Achdout, H., et al. (2005). The
involvement of NK cells in ankylos-
ing spondylitis. Int. Immunol. 17,
837–845.
Barbour, J. D., Sriram, U., Caillier, S.
J., Levy, J. A., Hecht, F. M., and
Oksenberg, J. R. (2007). Synergy
or independence? Deciphering the
interaction of HLA Class I and NK
cell KIR alleles in early HIV-1 disease
progression. PLoS Pathog. 3, e43. doi:
10.1371/journal.ppat.0030043
Besson, C., Roetynck, S., Williams,
F., Orsi, L., Amiel, C., Lepende-
ven, C., et al. (2007). Association
of killer cell immunoglobulin-like
receptor genes with Hodgkin’s lym-
phoma in a familial study. PLoS ONE
2, e406. doi: 10.1371/journal.pone.
0000406
Biassoni, R., Falco, M., Cambiaggi, A.,
Costa, P., Verdiani, S., Pende, D.,
et al. (1995). Amino acid substitu-
tions can inﬂuence the natural killer
(NK)-mediated recognition of HLA-
C molecules. Role of serine-77 and
lysine-80 in the target cell protection
from lysis mediated by “group 2” or
“group1”NKclones. J. Exp. Med. 182,
605–609.
Bonagura, V. R., Du, Z., Ashouri, E.,
Luo, L., Hatam, L. J., Devoti, J.
A., et al. (2010). Activating killer
cell immunoglobulin-like receptors
3DS1 and 2DS1 protect against devel-
oping the severe form of recurrent
respiratory papillomatosis. Hum.
Immunol. 71, 212–219.
Boulet, S., Sharaﬁ, S., Simic, N.,
Bruneau, J., Routy, J. P., Tsoukas,
C. M., et al. (2008). Increased pro-
portion of KIR3DS1 homozygotes in
HIV-exposed uninfected individuals.
AIDS 22, 595–599.
Boyington, J. C., Motyka, S. A., Schuck,
P., Brooks, A. G., and Sun, P. D.
(2000). Crystal structure of an NK
cell immunoglobulin-like receptor in
complex with its class I MHC ligand.
Nature 405, 537–543.
Campbell, K. S., and Purdy, A.
K. (2011). Structure/function of
human killer cell immunoglobulin-
like receptors: lessons from polymor-
phisms, evolution, crystal structures
and mutations. Immunology 132,
315–325.
Carr, W. H., Pando, M. J., and Parham,
P. (2005). KIR3DL1 polymorphisms
that affect NK cell inhibition byHLA-
Bw4 ligand. J. Immunol. 175, 5222–
5229.
Carr, W. H., Rosen, D. B., Arase,
H., Nixon, D. F., Michaelsson, J.,
and Lanier, L. L. (2007). Cutting
Edge: KIR3DS1, a gene implicated
in resistance to progression to AIDS,
encodes a DAP12-associated receptor
expressed on NK cells that triggers
NK cell activation. J. Immunol. 178,
647–651.
Carrington, M., Wang, S., Martin,
M. P., Gao, X., Schiffman, M.,
Cheng, J., et al. (2005). Hierarchy
of resistance to cervical neoplasia
mediated by combinations of killer
immunoglobulin-like receptor and
human leukocyte antigen loci. J. Exp.
Med. 201, 1069–1075.
Cella,M., Longo,A., Ferrara,G. B., Stro-
minger, J. L., andColonna,M. (1994).
NK3-speciﬁc natural killer cells are
selectively inhibited by Bw4-positive
HLA alleles with isoleucine 80. J. Exp.
Med. 180, 1235–1242.
Chan, H. W., Kurago, Z. B., Stewart,
C. A., Wilson, M. J., Martin, M.
P., Mace, B. E., et al. (2003). DNA
methylation maintains allele-speciﬁc
KIR gene expression in human nat-
ural killer cells. J. Exp. Med. 197,
245–255.
Chan, H. W., Miller, J. S., Moore,
M. B., and Lutz, C. T. (2005).
Epigenetic control of highly homol-
ogous killer Ig-like receptor gene
alleles. J. Immunol. 175, 5966–
5974.
Crum, K. A., Logue, S. E., Curran, M.
D., and Middleton, D. (2000). Devel-
opment of a PCR-SSOP approach
capable of deﬁning the natural killer
cell inhibitory receptor (KIR) gene
sequence repertoires. Tissue Antigens
56, 313–326.
Davies,G. E., Locke, S.M.,Wright, P.W.,
Li, H., Hanson, R. J., Miller, J. S., et al.
(2007). Identiﬁcation of bidirectional
promoters in the human KIR genes.
Genes Immun. 8, 245–253.
Diaz-Pena, R., Blanco-Gelaz, M. A.,
and Lopez-Larrea, C. (2009). KIR
genes and their role in spondy-
loarthropathies. Adv. Exp. Med. Biol.
649, 286–299.
Diaz-Pena, R., Blanco-Gelaz, M. A.,
Suarez-Alvarez, B., Martinez-Borra,
J., Lopez-Vazquez, A., Alonso-Arias,
R., et al. (2008). Activating KIR
genes are associated with ankylos-
ing spondylitis in Asian populations.
Hum. Immunol. 69, 437–442.
Diaz-Pena, R., Vidal-Castineira, J. R.,
Alonso-Arias, R., Suarez-Alvarez, B.,
Vicario, J. L., Solana, R., et al. (2010).
Association of the KIR3DS1*013
and KIR3DL1*004 alleles with sus-
ceptibility to ankylosing spondyli-
tis. Arthritis Rheum. 62, 1000–
1006.
Dohring,C., Samaridis, J., andColonna,
M. (1996). Alternatively spliced
forms of human killer inhibitory
receptors. Immunogenetics 44,
227–230.
Dougados, M., and Baeten, D. (2011).
Spondyloarthritis. Lancet 377, 2127–
2137.
Fadda, L., Borhis, G., Ahmed, P.,
Cheent, K., Pageon, S. V., Cazaly,
A., et al. (2010). Peptide antagonism
as a mechanism for NK cell activa-
tion. Proc. Natl. Acad. Sci. U.S.A. 107,
10160–10165.
Fadda, L., O’Connor, G. M., Kumar,
S., Piechocka-Trocha, A., Gar-
diner, C. M., Carrington, M., et al.
(2011). Common HIV-1 peptide
variants mediate differential binding
of KIR3DL1 to HLA-Bw4 molecules.
J. Virol. 85, 5970–5974.
Fan, Q. R., Long, E. O., and Wiley, D.
C. (2001). Crystal structure of the
human natural killer cell inhibitory
receptor KIR2DL1-HLA-Cw4 com-
plex. Nat. Immunol. 2, 452–460.
Faure, M., and Long, E. O. (2002).
KIR2DL4 (CD158d), an NK cell-
activating receptor with inhibitory
potential. J. Immunol. 168, 6208–
6214.
Foley, B. A., De Santis, D., Van Beelen,
E., Lathbury, L. J., Christiansen, F. T.,
and Witt, C. S. (2008). The reactivity
of Bw4+ HLA-B and HLA-A alle-
les with KIR3DL1: implications for
patient and donor suitability for hap-
loidentical stem cell transplantations.
Blood 112, 435–443.
Gabriel, I. H., Sergeant, R., Szydlo,
R., Apperley, J. F., Delavallade, H.,
Alsuliman, A., et al. (2010). Inter-
action between KIR3DS1 and HLA-
Bw4 predicts for progression-free
survival after autologous stem cell
transplantation in patients with mul-
tiple myeloma. Blood 116, 2033–
2039.
Gagne, K., Busson, M., Bignon, J. D.,
Balere-Appert, M. L., Loiseau, P.,
Dormoy, A., et al. (2009). Donor
KIR3DL1/3DS1 gene and recipi-
ent Bw4 KIR ligand as prognostic
markers for outcome in unrelated
hematopoietic stem cell transplanta-
tion. Biol. Blood Marrow Transplant.
15, 1366–1375.
Gardiner, C. M., Guethlein, L. A.,
Shilling, H. G., Pando, M., Carr,
W. H., Rajalingam, R., et al. (2001).
Different NK cell surface phenotypes
deﬁned by the DX9 antibody are due
to KIR3DL1 gene polymorphism. J.
Immunol. 166, 2992–3001.
Gaudieri, S., Desantis, D.,Mckinnon, E.,
Moore, C., Nolan,D.,Witt, C. S., et al.
(2005). Killer immunoglobulin-like
receptors and HLA act both inde-
pendently and synergistically tomod-
ify HIV disease progression. Genes
Immun. 6, 683–690.
Gendzekhadze, K., Norman, P. J., Abi-
Rached, L., Graef, T., Moesta, A.
K., Layrisse, Z., et al. (2009). Co-
evolutionof KIR2DL3withHLA-C in
a human population retaining min-
imal essential diversity of KIR and
HLA class I ligands. Proc. Natl. Acad.
Sci. U.S.A. 106, 18692–18697.
Gendzekhadze, K., Norman, P. J., Abi-
Rached, L., Layrisse, Z., and Parham,
P. (2006). High KIR diversity in
Amerindians is maintained using few
gene-content haplotypes. Immuno-
genetics 58, 474–480.
Gillespie, G. M., Bashirova, A., Dong,
T., Mcvicar, D. W., Rowland-Jones,
S. L., and Carrington, M. (2007).
Lack of KIR3DS1 binding to MHC
class I Bw4 tetramers in complex with
CD8+ T cell epitopes. AIDS Res.
Hum. Retroviruses 23, 451–455.
Gourraud, P. A.,Meenagh,A., Cambon-
Thomsen, A., and Middleton, D.
(2010). Linkage disequilibrium orga-
nization of the human KIR super-
locus: implications for KIR data anal-
yses. Immunogenetics 62, 729–740.
Guethlein, L. A., Abi-Rached, L., Ham-
mond, J. A., and Parham, P. (2007).
The expanded cattle KIR genes are
orthologous to the conserved single-
copy KIR3DX1 gene of primates.
Immunogenetics 59, 517–522.
Frontiers in Immunology | NK Cell Biology November 2012 | Volume 3 | Article 326 | 8
“ﬁmmu-03-00326” — 2012/11/1 — 14:43 — page 9 — #9
Körner and Altfeld Biology of KIR3DS1
Gumperz, J. E., Litwin,V., Phillips, J. H.,
Lanier, L. L., and Parham, P. (1995).
The Bw4 public epitope of HLA-B
molecules confers reactivity with nat-
ural killer cell clones that express
NKB1, a putative HLA receptor. J.
Exp. Med. 181, 1133–1144.
Hansasuta, P.,Dong, T., Thananchai,H.,
Weekes, M., Willberg, C., Aldemir,
H., et al. (2004). Recognitionof HLA-
A3 and HLA-A11 by KIR3DL2 is
peptide-speciﬁc. Eur. J. Immunol. 34,
1673–1679.
Harvey, D., Pointon, J. J., Sleator,
C., Meenagh, A., Farrar, C., Sun,
J. Y., et al. (2009). Analysis of
killer immunoglobulin-like receptor
genes in ankylosing spondylitis. Ann.
Rheum. Dis. 68, 595–598.
Hiby, S. E., Apps, R., Sharkey, A. M.,
Farrell, L. E., Gardner, L., Mul-
der, A., et al. (2010). Maternal acti-
vating KIRs protect against human
reproductive failuremediated by fetal
HLA-C2. J. Clin. Invest. 120, 4102–
4110.
Hiby, S. E., Regan, L., Lo, W., Far-
rell, L., Carrington, M., and Mof-
fett, A. (2008). Association of mater-
nal killer-cell immunoglobulin-like
receptors and parental HLA-C geno-
types with recurrent miscarriage.
Hum. Reprod. 23, 972–976.
Hiby, S. E., Walker, J. J., O’Shaughnessy
K, M., Redman, C. W., Carrington,
M., Trowsdale, J., et al. (2004). Com-
binations of maternal KIR and fetal
HLA-C genes inﬂuence the risk of
preeclampsia and reproductive suc-
cess. J. Exp. Med. 200, 957–965.
Hickman, H. D., Luis, A. D., Bardet, W.,
Buchli, R., Battson, C. L., Shearer, M.
H., et al. (2003). Cutting edge: class I
presentation of host peptides follow-
ing HIV infection. J. Immunol. 171,
22–26.
Hollenbach, J. A., Meenagh, A., Sleator,
C., Alaez, C., Bengoche, M., Canossi,
A., et al. (2010). Report from the
killer immunoglobulin-like receptor
(KIR) anthropology component of
the 15th International Histocompati-
bilityWorkshop: worldwide variation
in the KIR loci and further evidence
for the co-evolution of KIR andHLA.
Tissue Antigens 76, 9–17.
Hsu, K. C., Chida, S., Geraghty, D. E.,
and Dupont, B. (2002). The killer cell
immunoglobulin-like receptor (KIR)
genomic region: gene-order, hap-
lotypes and allelic polymorphism.
Immunol. Rev. 190, 40–52.
Jamil, K. M., and Khakoo, S. I. (2011).
KIR/HLA interactions and pathogen
immunity. J. Biomed. Biotechnol.
2011, 298348.
Jiao, Y. L., Zhang, B. C., You, L., Li,
J. F., Zhang, J., Ma, C. Y., et al.
(2010). Polymorphisms of KIR gene
and HLA-C alleles: possible asso-
ciation with susceptibility to HLA-
B27-positive patientswith ankylosing
spondylitis. J. Clin. Immunol. 30,
840–844.
Karabon, L., Jedynak, A., Giebel,
S., Wolowiec, D., Kielbinski, M.,
Woszczyk, D., et al. (2011). KIR/HLA
gene combinations inﬂuence sus-
ceptibility to B-cell chronic lym-
phocytic leukemia and the clinical
course of disease. Tissue Antigens 78,
129–138.
Khakoo, S. I., Geller, R., Shin, S., Jenk-
ins, J. A., and Parham, P. (2002).
The D0 domain of KIR3D acts as
a major histocompatibility complex
class I binding enhancer. J. Exp. Med.
196, 911–921.
Kim, S., Sunwoo, J. B., Yang, L., Choi, T.,
Song, Y. J., French, A. R., et al. (2008).
HLA alleles determine differences in
human natural killer cell responsive-
ness and potency. Proc. Natl. Acad.
Sci. U.S.A. 105, 3053–3058.
Lanier, L. L., Corliss, B. C., Wu,
J., Leong, C., and Phillips, J.
H. (1998). Immunoreceptor DAP12
bearing a tyrosine-based activation
motif is involved in activating NK
cells. Nature 391, 703–707.
Li, H., Pascal, V., Martin, M.
P., Carrington, M., and Ander-
son, S. K. (2008). Genetic control
of variegated KIR gene expression:
polymorphisms of the bi-directional
KIR3DL1 promoter are associated
with distinct frequencies of gene
expression. PLoS Genet. 4, e1000254.
doi: 10.1371/journal.pgen.1000254
Li, H., Peng, S. L., Cui, Y., Fu, Q.
X., Zhou, Y., Wang, Q. L., et al.
(2010). Kinetics of interaction of
HLA-B2705 with natural killer cell
immunoglobulin-like receptor 3DS1.
Protein Pept. Lett. 17, 547–554.
Litwin, V., Gumperz, J., Parham, P.,
Phillips, J.H., andLanier, L. L. (1994).
NKB1: a natural killer cell receptor
involved in the recognition of poly-
morphic HLA-B molecules. J. Exp.
Med. 180, 537–543.
Long, B. R., Ndhlovu, L. C., Oksen-
berg, J. R., Lanier, L. L., Hecht,
F. M., Nixon, D. F., et al. (2008).
Conferral of enhanced natural killer
cell function by KIR3DS1 in early
human immunodeﬁciency virus type
1 infection. J. Virol. 82, 4785–4792.
Lopez-Larrea, C., Blanco-Gelaz, M.
A., Torre-Alonso, J. C., Bruges
Armas, J., Suarez-Alvarez, B.,
Pruneda, L., et al. (2006). Contribu-
tion of KIR3DL1/3DS1 to ankylos-
ing spondylitis in human leukocyte
antigen-B27 Caucasian populations.
Arthritis Res. Ther. 8, R101.
Lopez-Vazquez, A., Rodrigo, L.,
Martinez-Borra, J., Perez, R.,
Rodriguez, M., Fdez-Morera, J.
L., et al. (2005). Protective effect
of the HLA-Bw4I80 epitope and
the killer cell immunoglobulin-like
receptor 3DS1 gene against the devel-
opment of hepatocellular carcinoma
in patients with hepatitis C virus
infection. J. Infect. Dis. 192, 162–165.
Maenaka, K., Juji, T., Nakayama, T.,
Wyer, J. R., Gao, G. F., Maenaka, T.,
et al. (1999). Killer cell immunoglob-
ulin receptors and T cell receptors
bind peptide-major histocompatibil-
ity complex class I with distinct ther-
modynamic and kinetic properties. J.
Biol. Chem. 274, 28329–28334.
Malnati, M. S., Peruzzi, M., Parker,
K. C., Biddison, W. E., Ciccone, E.,
Moretta, A., et al. (1995). Peptide
speciﬁcity in the recognition of MHC
class I by natural killer cell clones.
Science 267, 1016–1018.
Mandelboim, O., Wilson, S. B., Vales-
Gomez, M., Reyburn, H. T., and
Strominger, J. L. (1997). Self and viral
peptides can initiate lysis by autolo-
gous natural killer cells. Proc. Natl.
Acad. Sci. U.S.A. 94, 4604–4609.
Marcenaro, E., Carlomagno, S., Pesce,
S., Della Chiesa, M., Moretta, A., and
Sivori, S. (2011). Role of alloreac-
tive KIR2DS1(+) NK cells in hap-
loidentical hematopoietic stem cell
transplantation. J. Leukoc. Biol. 90,
661–667.
Marsh, S. G., Parham, P., Dupont, B.,
Geraghty, D. E., Trowsdale, J., Mid-
dleton, D., et al. (2003). Killer-cell
immunoglobulin-like receptor (KIR)
nomenclature report, 2002. Tissue
Antigens 62, 79–86.
Martin, M. P., Bashirova, A., Traherne,
J., Trowsdale, J., and Carrington, M.
(2003). Cutting edge: expansion of
the KIR locus by unequal crossing
over. J. Immunol. 171, 2192–2195.
Martin, M. P., Gao, X., Lee, J. H., Nel-
son, G. W., Detels, R., Goedert, J.
J., et al. (2002). Epistatic interaction
between KIR3DS1 and HLA-B delays
the progression to AIDS. Nat. Genet.
31, 429–434.
Martin, M. P., Pascal, V., Yeager, M.,
Phair, J., Kirk, G. D., Hoots, K., et al.
(2007a). Amutation in KIR3DS1 that
results in truncation and lack of cell
surface expression. Immunogenetics
59, 823–829.
Martin, M. P., Qi, Y., Gao, X., Yamada,
E., Martin, J. N., Pereyra, F., et al.
(2007b). Innate partnership of HLA-
B and KIR3DL1 subtypes against
HIV-1. Nat. Genet. 39, 733–740.
Meiring, H. D., Soethout, E. C., Poelen,
M.C.,Mooibroek,D.,Hoogerbrugge,
R., Timmermans, H., et al. (2006).
Stable isotope tagging of epitopes: a
highly selective strategy for the iden-
tiﬁcation of major histocompatibility
complex class I-associated peptides
induced upon viral infection. Mol.
Cell. Proteomics 5, 902–913.
Moesta, A. K., Norman, P. J., Yawata,
M., Yawata, N., Gleimer, M., and
Parham, P. (2008). Synergistic poly-
morphism at two positions distal
to the ligand-binding site makes
KIR2DL2 a stronger receptor for
HLA-C than KIR2DL3. J. Immunol.
180, 3969–3979.
Moretta, A., Vitale, M., Bottino,
C., Orengo, A. M., Morelli, L.,
Augugliaro, R., et al. (1993). P58
molecules as putative receptors for
major histocompatibility complex
(MHC) class I molecules in human
natural killer (NK) cells. Anti-p58
antibodies reconstitute lysis of MHC
class I-protected cells in NK clones
displaying different speciﬁcities. J.
Exp. Med. 178, 597–604.
Morvan, M., David, G., Sebille, V.,
Perrin, A., Gagne, K., Willem, C.,
et al. (2008). Autologous and allo-
geneicHLAKIR ligand environments
and activating KIR control KIR NK-
cell functions. Eur. J. Immunol. 38,
3474–3486.
Morvan, M., Willem, C., Gagne, K.,
Kerdudou, N., David, G., Sebille, V.,
et al. (2009). Phenotypic and func-
tional analyses of KIR3DL1+ and
KIR3DS1+ NK cell subsets demon-
strate differential regulation by Bw4
molecules and induced KIR3DS1
expression on stimulated NK cells. J.
Immunol. 182, 6727–6735.
Mousavi, T., Poormoghim, H., Moradi,
M., Tajik, N., Shahsavar, F., and
Asadifar, B. (2010). Inhibitory killer
cell immunoglobulin-like receptor
KIR3DL1 in combination with HLA-
B Bw4iso protect against ankylos-
ing spondylitis. Iran J. Immunol. 7,
88–95.
Norman, P. J., Abi-Rached, L.,
Gendzekhadze, K., Korbel, D.,
Gleimer, M., Rowley, D., et al.
(2007). Unusual selection on the
KIR3DL1/S1 natural killer cell recep-
tor in Africans. Nat. Genet. 39,
1092–1099.
O’Connell, K. A., Han, Y., Williams,
T. M., Siliciano, R. F., and Blank-
son, J. N. (2009). Role of natural
killer cells in a cohort of elite suppres-
sors: low frequency of the protective
KIR3DS1 allele and limited inhibi-
tion of human immunodeﬁciency
virus type 1 replication in vitro. J.
Virol. 83, 5028–5034.
O’Connor, G. M., Guinan, K. J., Cun-
ningham, R. T., Middleton, D.,
Parham, P., and Gardiner, C. M.
www.frontiersin.org November 2012 | Volume 3 | Article 326 | 9
“ﬁmmu-03-00326” — 2012/11/1 — 14:43 — page 10 — #10
Körner and Altfeld Biology of KIR3DS1
(2007). Functional polymorphism
of the KIR3DL1/S1 receptor on
human NK cells. J. Immunol. 178,
235–241.
O’Connor, G. M., Seich Al Basatena,
N. K., Olavarria, V., Macnamara, A.,
Vine, A., Ying, Q., et al. (2012). In
contrast to HIV, KIR3DS1 does not
inﬂuence outcome in HTLV-1 retro-
viral infection. Hum. Immunol. 73,
783–737.
O’Connor, G. M., Yamada, E., Ram-
persaud, A., Thomas, R., Carrington,
M., and Mcvicar, D. W. (2011). Anal-
ysis of binding of KIR3DS1*014 to
HLA suggests distinct evolutionary
history of KIR3DS1. J. Immunol. 187,
2162–2171.
Pando, M. J., Gardiner, C. M.,
Gleimer, M., Mcqueen, K. L., and
Parham, P. (2003). The protein made
from a common allele of KIR3DL1
(3DL1*004) is poorly expressed at cell
surfaces due to substitution at posi-
tions 86 in Ig domain 0 and 182
in Ig domain 1. J. Immunol. 171,
6640–6649.
Parham, P., Norman, P. J., Abi-Rached,
L., and Guethlein, L. A. (2011). Vari-
able NK cell receptors exempliﬁed
by human KIR3DL1/S1. J. Immunol.
187, 11–19.
Pascal, V., Yamada, E., Martin, M. P.,
Alter, G., Altfeld, M., Metcalf, J. A.,
et al. (2007). Detection of KIR3DS1
on the cell surface of peripheral blood
NK cells facilitates identiﬁcation of a
novel null allele and assessment of
KIR3DS1 expression during HIV-1
infection. J. Immunol. 179, 1625–
1633.
Pelak, K., Need, A. C., Fellay, J., Shi-
anna, K. V., Feng, S., Urban, T. J., Ge,
D., et al. (2011). Copy number vari-
ation of KIR genes inﬂuences HIV-1
control. PLoS Biol. 9, e1001208. doi:
10.1371/journal.pbio.1001208
Peruzzi, M., Wagtmann, N., and
Long, E. O. (1996). A p70 killer
cell inhibitory receptor speciﬁc for
several HLA-B allotypes discrimi-
nates among peptides bound toHLA-
B*2705. J. Exp. Med. 184, 1585–1590.
Purdy, A. K., and Campbell, K. S.
(2009). Natural killer cells and can-
cer: regulation by the killer cell Ig-like
receptors (KIR). Cancer Biol. Ther. 8,
2211–2220.
Qi, Y., Martin, M. P., Gao, X.,
Jacobson, L., Goedert, J. J., Buch-
binder, S., et al. (2006). KIR/HLA
pleiotropism: protection against
both HIV and opportunistic infec-
tions. PLoS Pathog. 2, e79. doi:
10.1371/journal.ppat.0020079
Rajagopalan, S., and Long, E. O.
(1997). The direct binding of a
p58 killer cell inhibitory receptor to
human histocompatibility leukocyte
antigen (HLA)-Cw4 exhibits pep-
tide selectivity. J. Exp. Med. 185,
1523–1528.
Rajagopalan, S., and Long, E. O. (1999).
A human histocompatibility leuko-
cyte antigen (HLA)-G-speciﬁc recep-
tor expressedonall natural killer cells.
J. Exp. Med. 189, 1093–1100.
Robinson, J., Mistry, K., Mcwilliam,
H., Lopez, R., and Marsh, S. G.
(2010). IPD – the immuno polymor-
phism database. Nucleic Acids Res. 38,
D863– D869.
Sambrook, J. G., Bashirova, A., Ander-
sen, H., Piatak, M., Vernikos,
G. S., Coggill, P., et al. (2006).
Identiﬁcation of the ancestral killer
immunoglobulin-like receptor gene
in primates. BMC Genomics 7, 209.
doi: 10.1186/1471-2164-7-209
Santourlidis, S., Graffmann, N., Christ,
J., and Uhrberg, M. (2008). Lineage-
speciﬁc transition of histone signa-
tures in the killer cell Ig-like receptor
locus from hematopoietic progeni-
tor to NK cells. J. Immunol. 180,
418–425.
Santourlidis, S., Trompeter, H. I.,Wein-
hold, S., Eisermann, B., Meyer, K.
L., Wernet, P., et al. (2002). Crucial
role of DNA methylation in determi-
nation of clonally distributed killer
cell Ig-like receptor expression pat-
terns in NK cells. J. Immunol. 169,
4253–4261.
Sharma, D., Bastard, K., Guethlein,
L. A., Norman, P. J., Yawata, N.,
Yawata, M., et al. (2009). Dimorphic
motifs in D0 and D1+D2 domains
of killer cell Ig-like receptor 3DL1
combine to form receptors with high,
moderate, andnoavidity for the com-
plex of a peptide derived from HIV
and HLA-A*2402. J. Immunol. 183,
4569–4582.
Stern, M., Ruggeri, L., Capanni, M.,
Mancusi, A., and Velardi, A. (2008).
Human leukocyte antigens A23, A24,
and A32 but not A25 are ligands for
KIR3DL1. Blood 112, 708–710.
Stewart, C. A., Laugier-Anfossi, F., Vely,
F., Saulquin, X., Riedmuller, J., Tis-
serant, A., et al. (2005). Recognition
of peptide-MHC class I complexes
by activating killer immunoglobulin-
like receptors. Proc. Natl. Acad. Sci.
U.S.A. 102, 13224–13229.
Stewart,C.A., vanBergen, J., andTrows-
dale, J. (2003). Different and diver-
gent regulation of the KIR2DL4 and
KIR3DL1 promoters. J. Immunol.
170, 6073–6081.
Stulberg, M. J., Wright, P. W., Dang, H.,
Hanson, R. J., Miller, J. S., and Ander-
son, S. K. (2007). Identiﬁcation of
distal KIR promoters and transcripts.
Genes Immun. 8, 124–130.
Tajik, N., Shahsavar, F., Poor-
moghim, H., Radjabzadeh, M.
F., Mousavi, T., and Jalali, A.
(2011). KIR3DL1+HLA-B Bw4Ile80
and KIR2DS1+HLA-C2 combina-
tions are both associated with anky-
losing spondylitis in the Iranian pop-
ulation. Int. J. Immunogenet. 38,
403–409.
Thananchai, H., Gillespie, G., Martin,
M. P., Bashirova, A., Yawata, N.,
Yawata, M., et al. (2007). Cutting
Edge: allele-speciﬁc and peptide-
dependent interactions between
KIR3DL1 and HLA-A and HLA-B. J.
Immunol. 178, 33–37.
Thomas,G. P., andBrown,M.A. (2010).
Genetics and genomics of ankylos-
ing spondylitis. Immunol. Rev. 233,
162–180.
Thomas, R., Yamada, E., Alter, G., Mar-
tin, M. P., Bashirova, A. A., Norman,
P. J., et al. (2008). Novel KIR3DL1
alleles and their expression levels
on NK cells: convergent evolution
of KIR3DL1 phenotype variation? J.
Immunol. 180, 6743–6750.
Tomescu, C., Abdulhaqq, S., and Mon-
taner, L. J. (2011). Evidence for
the innate immune response as a
correlate of protection in human
immunodeﬁciency virus (HIV)-1
highly exposed seronegative subjects
(HESN). Clin. Exp. Immunol. 164,
158–169.
Tomescu, C., Duh, F. M., Lanier, M. A.,
Kapalko, A., Mounzer, K. C., Martin,
M. P., et al. (2010). Increased plasma-
cytoid dendritic cell maturation and
natural killer cell activation in HIV-
1 exposed, uninfected intravenous
drug users. AIDS 24, 2151–2160.
Traherne, J. A., Martin, M., Ward,
R., Ohashi, M., Pellett, F., Glad-
man, D., et al. (2010). Mechanisms
of copy number variation and hybrid
gene formation in the KIR immune
gene complex. Hum. Mol. Genet. 19,
737–751.
Trowsdale, J. (2001). Genetic and func-
tional relationships between MHC
andNK receptor genes. Immunity 15,
363–374.
Trundley, A., Frebel, H., Jones,
D., Chang, C., and Trowsdale, J.
(2007). Allelic expression patterns of
KIR3DS1 and 3DL1 using the Z27
and DX9 antibodies. Eur. J. Immunol.
37, 780–787.
Uhrberg, M., Valiante, N. M., Shum,
B. P., Shilling, H. G., Lienert-
Weidenbach, K., Corliss, B., et al.
(1997). Human diversity in killer cell
inhibitory receptor genes. Immunity
7, 753–763.
Vales-Gomez, M., Reyburn, H. T.,
Erskine, R. A., and Strominger,
J. (1998). Differential binding to
HLA-C of p50-activating and p58-
inhibitory natural killer cell recep-
tors. Proc. Natl. Acad. Sci. U.S.A. 95,
14326–14331.
Valiante, N. M., Uhrberg, M., Shilling,
H. G., Lienert-Weidenbach, K.,
Arnett, K. L., D’Andrea, A., et al.
(1997). Functionally and structurally
distinct NK cell receptor reper-
toires in the peripheral blood of
two human donors. Immunity 7,
739–751.
van Bergen, J., Stewart, C. A., Van
Den Elsen, P. J., and Trowsdale, J.
(2005). Structural and functional dif-
ferences between the promoters of
independently expressed killer cell Ig-
like receptors. Eur. J. Immunol. 35,
2191–2199.
Venstrom, J. M., Gooley, T. A., Spell-
man, S., Pring, J., Malkki, M.,
Dupont, B., et al. (2010). Donor acti-
vating KIR3DS1 is associated with
decreased acute GVHD in unrelated
allogeneic hematopoietic stem cell
transplantation. Blood 115, 3162–
3165.
Verheyden, S., Schots, R., Duquet, W.,
and Demanet, C. (2005). A deﬁned
donor activating natural killer cell
receptor genotype protects against
leukemic relapse after related HLA-
identical hematopoietic stem cell
transplantation. Leukemia 19, 1446–
1451.
Vivian, J. P., Duncan, R. C.,
Berry, R., O’Connor, G. M.,
Reid, H. H., Beddoe, T., et al.
(2011). Killer cell immunoglobulin-
like receptor 3DL1-mediated recog-
nition of human leukocyte antigen B.
Nature 479, 401–405.
Vivier, E., Nunes, J. A., and Vely,
F. (2004). Natural killer cell signal-
ing pathways. Science 306, 1517–
1519.
Wang, S., Li, G., Ge, R., Duan, Z., Zeng,
Z., Zhang, T., et al. (2012). Associ-
ation of KIR genotype with suscep-
tibility to HLA-B27-positive anky-
losing spondylitis. Mod. Rheuma-
tol. doi: 10.1007/s10165-012-0692-z
[Epub ahead of print].
Williams, F., Maxwell, L. D., Half-
penny, I. A., Meenagh, A., Sleator, C.,
Curran, M. D., et al. (2003). Multi-
ple copies of KIR 3DL/S1 and KIR
2DL4 genes identiﬁed in a number
of individuals. Hum. Immunol. 64,
729–732.
Wilson, M. J., Torkar, M., Haude, A.,
Milne, S., Jones, T., Sheer, D., et al.
(2000). Plasticity in the organization
and sequences of human KIR/ILT
gene families. Proc. Natl. Acad. Sci.
U.S.A. 97, 4778–4783.
Winter, C. C., and Long, E. O. (1997).
A single amino acid in the p58 killer
Frontiers in Immunology | NK Cell Biology November 2012 | Volume 3 | Article 326 | 10
“ﬁmmu-03-00326” — 2012/11/1 — 14:43 — page 11 — #11
Körner and Altfeld Biology of KIR3DS1
cell inhibitory receptor controls the
ability of natural killer cells to dis-
criminate between the two groups of
HLA-C allotypes. J. Immunol. 158,
4026–4028.
Wu, J., and Lanier, L. L. (2003). Natu-
ral killer cells and cancer. Adv. Cancer
Res. 90, 127–156.
Yawata, M., Yawata, N., Draghi, M.,
Little, A. M., Partheniou, F., and
Parham, P. (2006). Roles forHLA and
KIR polymorphisms in natural killer
cell repertoire selection and modula-
tion of effector function. J. Exp. Med.
203, 633–645.
Zappacosta, F., Borrego, F., Brooks, A.
G., Parker, K. C., and Coligan, J. E.
(1997). Peptides isolated from HLA-
Cw*0304 confer different degrees of
protection from natural killer cell-
mediated lysis. Proc. Natl. Acad. Sci.
U.S.A. 94, 6313–6318.
Zhi-Ming, L., Yu-Lian, J., Zhao-
Lei, F., Chun-Xiao, W., Zhen-
Fang, D., Bing-Chang, Z., et al.
(2007). Polymorphisms of killer cell
immunoglobulin-like receptor gene:
possible association with suscepti-
bility to or clearance of hepatitis
B virus infection in Chinese Han
population. Croat. Med. J. 48,
800–806.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 12 June 2012; accepted: 09
October 2012; published online: 01
November 2012.
Citation: Körner C and Altfeld M (2012)
Role of KIR3DS1 in human diseases.
Front. Immun. 3:326. doi: 10.3389/
ﬁmmu.2012.00326
This article was submitted to Frontiers in
NK Cell Biology, a specialty of Frontiers
in Immunology.
Copyright © 2012 Körner and Alt-
feld. This is an open-access article
distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, pro-
vided the original authors and source
are credited and subject to any copy-
right notices concerning any third-party
graphics etc.
www.frontiersin.org November 2012 | Volume 3 | Article 326 | 11
